RO7759065
- Generic Name
- RO7759065
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 310
- Registration Number
- NCT06488716
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇨🇦Sir Mortimer B Davis Jewish General Hospital-3755 Cote Sainte-Catherine, Montreal, Quebec, Canada
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath